SNRPB is a mediator for cellular response to cisplatin in non-small-cell lung cancer

Liu, Nianli; Chen, Aoxing; Feng, Ning; Liu, Xiaochen; Zhang, Longzhen

doi:10.1007/s12032-021-01502-0

Cited by 10 publications

(6 citation statements)

References 29 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous study reported that SNRPB promotes the tumor formation of NSCLC by regulating RAB26 and SNRPB may predict response to cisplatin-based chemotherapy for NSCLC patients ( Liu et al, 2019 ; Liu et al, 2021 ). Here, the mRNA expression of SNRPB was found to be upregulated in LUAD compared to non-cancer tissues.…”

Section: Discussionmentioning

confidence: 98%

SNRPD1/E/F/G Serve as Potential Prognostic Biomarkers in Lung Adenocarcinoma

Liu

Chen

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Objectives: Sm proteins (SNRPB/D1/D2/D3/E/F/G), involved in pre-mRNA splicing, were previously reported in the tumorigenesis of several cancers. However, their specific role in lung adenocarcinoma (LUAD) remains obscure. Our study aims to feature abnormal expressions and mutations of genes for Sm proteins and assess their potential as therapeutic targets via integrated bioinformatics analysis.Methods: In this research, we explored the expression pattern and prognostic worth of genes for Sm proteins in LUAD across TCGA, GEO, UALCAN, Oncomine, Metascape, David 6.8, and Kaplan-Meier Plotter, and confirmed its independent prognostic value via univariate and multivariate cox regression analysis. Meanwhile, their expression patterns were validated by RT-qPCR. Gene mutations and co-expression of genes for Sm proteins were analyzed by the cBioPortal database. The PPI network for Sm proteins in LUAD was visualized by the STRING and Cytoscape. The correlations between genes for Sm proteins and immune infiltration were analyzed by using the “GSVA” R package.Results: Sm proteins genes were found upregulated expression in both LUAD tissues and LUAD cell lines. Moreover, highly expressed mRNA levels for Sm proteins were strongly associated with short survival time in LUAD. Genes for Sm proteins were positively connected with the infiltration of Th2 cells, but negatively connected with the infiltration of mast cells, Th1 cells, and NK cells. Importantly, Cox regression analysis showed that high SNRPD1/E/F/G expression were independent risk factors for the overall survival of LUAD.Conclusion: Our study showed that SNRPD1/E/F/G could independently predict the prognostic outcome of LUAD and was correlated with immune infiltration. Also, this report laid the foundation for additional exploration on the potential treatment target’s role of SNRPD1/E/F/G in LUAD.

show abstract

Section: Discussionmentioning

confidence: 98%

SNRPD1/E/F/G Serve as Potential Prognostic Biomarkers in Lung Adenocarcinoma

Liu

Chen

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…The molecules B/D1/D2/D3/E/F/G are the core Sm proteins that make up splice snRNPs and have a significant role in the development of cancer, according to previous research [ 18 ]. SNRPB is significantly linked to cisplatin resistance in NSCLC, and overexpressed SNRPBs enhance the inhibitory effect of cisplatin on H460 cell-mediated xenografted tumors [ 19 , 20 ]. SNRPB can mediate RNA splicing and drive the proliferation and dryness of tumor cells in hepatocellular carcinoma.…”

Section: Discussionmentioning

confidence: 99%

Significance of Spliceosome-Related Genes in the Prediction of Prognosis and Treatment Strategies for Lung Adenocarcinoma

Yang

Huang

Fan

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

Background. The leading cause of cancer-related fatalities globally is lung cancer; lung adenocarcinoma (LUAD) is the most common histological type in it. The spliceosome plays an important role in a majority of malignancies. However, it is yet unclear how spliceosome-related genes affect patients with LUAD in terms of treatment course and prognosis. Methods. Spliceosome-related genes were assessed from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) database to obtain clinical information and gene expression in patients with LUAD. A spliceosome-related gene signature and prognostic model were constructed by using the least absolute shrinkage and selection operator (LASSO), time-dependent receiver operating characteristic (ROC), and nomogram. Immune infiltrate levels, mutation analysis, and pathway enrichment were predicted potential mechanisms of the signature by using single-sample gene set enrichment analysis (ssGSEA), Gene Set Cancer Analysis (GSCA) database, Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Ontology (GO) database. Then, a protein–protein interaction (PPI) network and transcription factor- (TF-) hub gene and drug mining network were also established by Cytoscape software. Results. Firstly, we constructed a prognostic model for 11 spliceosome signature genes. Based on the prognostic risk score, we stratified patients with LUAD into high- and low-risk groups. The high- and low-risk groups were closely related to the OS, tumor immune infiltration level, immune checkpoint molecules, and tumor mutation burden (TMB) of LUAD patients. Based on PPI networks, we also predict relevant TF genes that may regulate signature prognostic genes. Finally, drugs including oxaliplatin, arsenic trioxide, cisplatin, and sunitinib were excavated for the treatment of the 11 spliceosome signature genes in LUAD patients. Conclusion. In conclusion, this study is the first to explore the importance of spliceosome-related genes in the prognosis and treatment of LUAD. Through our study, we have innovatively provided potential prognosis genes and new therapeutic drug targets for the treatment of LUAD patients.

show abstract

“…The basic findings provide clues regarding the mechanisms of the adverse effects of SNRPB on tumor prognosis. SNRPB not only promotes tumor proliferation, migration, and metastasis but also maintains the stemness of tumor cells ( Zhan et al, 2020 ) and affects tumor responsiveness to therapy ( Liu et al, 2021 ). Therefore, SNRPB may be involved in many aspects, such as tumorigenesis, progression, metastasis, maintenance of stemness, and treatment responsiveness, acting with adverse effects on the prognosis of tumors.…”

Section: Discussionmentioning

confidence: 99%

“…The protein translated by these new mRNA variants may play an important role in tumorigenesis ( Correa et al, 2016 ; Liu et al, 2019 ; Peng et al, 2020 ; Zhan et al, 2020 ). The role of SNRPB in promoting tumorigenesis and progression has been observed in tumors such as non-small cell lung cancer (NSCLC) ( Liu et al, 2019 ; Liu et al, 2021 ), hepatocellular carcinoma (LIHC) ( Peng et al, 2020 ; Zhan et al, 2020 ; Li et al, 2022 ), glioblastoma (GBM) ( Correa et al, 2016 ), cervical cancer (CESC) ( Zhu et al, 2020 ), and thyroid carcinoma (THCA) ( Deng et al, 2022 ). However, the role of SNRPB in other tumors remains unclear.…”

Section: Introductionmentioning

confidence: 99%

The oncogenic role of SNRPB in human tumors: A pan-cancer analysis

Lu²,

Yu³

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

Purpose: The purpose of this study was to explore the oncogenic role of small nuclear ribonucleoprotein polypeptides B and B1 (SNRPB) in human tumors.Materials and methods: Study cases were acquired from The Cancer Genome Atlas database, the Gene Expression Omnibus database, The Human Protein Atlas, and the Clinical Proteomic Tumor Analysis Consortium. We then used the R package and several online tools to analyze and visualize the role of SNRPB across tumors.Results: We found that the expression of SNRPB was significantly increased in 28 of 33 tumors, and higher expression was observed in late pathological and TNM stages. Significantly decreased levels of SNRPB promoter methylation were observed in 12 tumors. SNRPB was found to be a risk factor for decreased overall survival in 10 tumors (p < 0.05), a risk factor for decreased disease-specific survival in 8 tumors (p < 0.05), and a risk factor for decreased progression-free interval in 7 tumors (p < 0.05). The PPI network of SNRPB and the top 100 coexpressed genes revealed that CDK1, CDC6, AURKB, CCNB1, CCNA2, and CDC45 were the most closely interacting genes across tumors. The GO and KEGG enrichment analyses revealed that SNRPB and the above genes were mainly enriched with respect to functions in cell cycle-related genetic material replication, assembly, and distribution. SNRPB was significantly associated with immune cell infiltration and the expression of immunomodulation-related genes in several but not all tumors.Conclusion and limitations: The expression of SNRPB was significantly elevated in almost all tumors, and the decreased promoter methylation level may contribute to the elevated expression of SNRPB. SNRPB may facilitate the progression of pathological and TNM stages and is a risk factor for unfavorable prognosis across tumors. However, our research was based on data obtained from public databases, without further validation of our findings at the cellular and animal levels. Therefore, further studies are needed to clarify the oncogenic mechanism of SNRPB and its potential as a therapeutic target.

show abstract

SNRPB is a mediator for cellular response to cisplatin in non-small-cell lung cancer

Cited by 10 publications

References 29 publications

SNRPD1/E/F/G Serve as Potential Prognostic Biomarkers in Lung Adenocarcinoma

SNRPD1/E/F/G Serve as Potential Prognostic Biomarkers in Lung Adenocarcinoma

Significance of Spliceosome-Related Genes in the Prediction of Prognosis and Treatment Strategies for Lung Adenocarcinoma

The oncogenic role of SNRPB in human tumors: A pan-cancer analysis

Contact Info

Product

Resources

About